CEL-SCI (CVM) announced it has completed its Breakthrough Medicine Designation application for Multikine for submission to the Saudi Food and Drug Authority in Saudi Arabia. Multikine is an immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer. The Breakthrough Designation Application is expected to be formally submitted to the SFDA on CEL-SCI’s behalf within the next few weeks by the Company’s prospective Saudi partner, one of the country’s premier pharmaceutical and healthcare companies. According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVM:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue